When conducting stock research, investors may want to take a look at what the covering analysts are saying about the company. Zacks Research provides an average broker rating which is compiled using polled sell-side analysts. After a recent scan, we can see that the current ABR for Cytokinetics, Incorporated (NASDAQ:CYTK) is 1.5. Research firms may use various terminologies to describe their stock recommendations. This particular rating falls on a numerical scale from 1 to 5. A 1 rating would point to a Strong Buy, and a score of 5 would indicate a Strong Sell rating. The average broker rating helps investors by offering a general feel for sell-side sentiment on company shares. We have also noted that 3 analysts currently have the stock rated as a Buy or Strong Buy.
Some investors may be struggling after adding the wrong stocks to the portfolio. Creating a specific plan for investing may help turn the ship around. The stock market is still producing plenty of green arrows, and investors need to be able to capitalize. It is quite reasonable to be optimistic about the investment environment heading into the second half of the year. The next couple of weeks may be the perfect time for investors to put the pedal down and try to develop a strategy that will beat the market over the next quarter. Most investors realize that there are no certainties when it comes to equity investing. It is never a guarantee that a stock or an index will go up or down from one day to the next. Investors who prepare themselves for any scenario should be in a much better place than those who don’t.
Viewing some popular support and resistance marks on shares of Cytokinetics, Incorporated (NASDAQ:CYTK), we can see that the 52-week high is presently $14.25, and the 52-week low is currently $5.91. When the stock is trading near the 52-week high or 52-week low, investors may be on the lookout for a potential break through the level. Looking at recent action, we can see that the stock has been trading near the $12.67 level. Investors may also want to track historical price activity. Over the past 12 weeks, the stock has changed 17.86%. Looking further back to the beginning of the calendar year, we note that shares have moved 100.47%. Over the previous 4 weeks, shares have seen a change of -4.88%. Over the last 5 trading sessions, the stock has moved -9.82%. Investors will be monitoring stock activity over the next few days to try and gauge which way the momentum is shifting.
Wall Street analysts tracking shares of Cytokinetics, Incorporated (NASDAQ:CYTK) have been closely monitor company activities and fundamentals. They often create research reports to assist with investment decisions. On a consensus basis, analysts have set a target price of $17.75 on the stock. This number may be different from the First Call consensus target estimate. Analysts that routinely cover the company may use different techniques in order to create a future target price. Because of the different methods, price targets may differ greatly from one analyst to another.
Shifting gears, we can see that the current quarter EPS consensus estimate for Cytokinetics, Incorporated (NASDAQ:CYTK) is -0.56. This EPS estimate is using 2 sell-side analysts polled by Zacks Research. For the prior reporting period, the company posted a quarterly EPS of -0.56. As we move through earnings season, all eyes will be on the company to see if they can beat analyst estimates and show improvement from the last quarter. When a company reports actual earnings numbers, the surprise factor can cause a stock price to realize increased activity. Investors and analysts will be closely watching to see how the earnings results impact the stock after the next release. Many investors will decide to be cautious around earnings releases and delay buy/sell moves until after the stock price has steadied.
Investors may be wondering how to tackle the markets at current levels. Many investors may feel like they have missed out on the markets getting to where they are today. It may be a case of missed trades or being too cautious, but a stellar forward thinking strategy may be just what is needed to get back on track. Studying various sectors may help provide some insight on where to go from here. Investors may become very familiar and comfortable with a certain sector, and they may be completely missing out on opportunities from other fast growing sectors. Investors may also need to take a long-term approach which may include creating a diversified portfolio that takes many different factors into consideration. With the enormous amount of uncertainty that follows the global investing world on a daily basis, it may be helpful for investors to be able to keep their emotions in check. Studying the hard data may prove to be very useful when trying to separate truth from fiction in the equity markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.